Andere Sprachen Bristol-Myers Squibb Company Xetra

Aktien

850501

US1101221083

BRM

Markt geschlossen - Xetra Andere Börsenplätze 17:35:32 26.06.2024			% 5 Tage	% 1. Jan.
39.85 ^EUR	+0.99%		+4.17%	-14.12%

26.06.	2seventy bio verkauft Hämophilie A-Kandidat und Gene-Editing-Technologie an Novo Nordisk; Aktien steigen nachbörslich	MT
26.06.	Top Midday Stories: Southwest senkt Q2-Prognose; HHS senkt Kosten für Medicare-Versicherte bei 64 Medikamenten; Bosch erwägt Übernahmeangebot für Whirlpool; Novo Nordisk verzeichnet Wertminderung in Höhe von 816,2 Millionen Dollar	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	26.06.
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	26.06.
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26.06.
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26.06.
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26.06.
European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab	24.06.
Bristol Myers : approbation accélérée en cancer colorectal	24.06.
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)	22.06.
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	22.06.
Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval	21.06.
US FDA approves Bristol Myers' colorectal cancer therapy	21.06.
Bristol-Myers Squibb Says EMA Validates Application for Subcutaneous Opdivo	21.06.
Bristol Myers : demande validée pour Opdivo sous-cutané	21.06.
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab	21.06.
Bristol Myers Squibb Announces European Medicines Agency Validates Extension Application to Introduce New Route of Administration (Subcutaneous Use) for Opdivo	21.06.
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024	20.06.
Bristol Myers : l'ex-CEO d'Agilent rejoint le conseil	19.06.
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors	18.06.
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024	18.06.
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment	18.06.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Schlagzeilen

Bristol-Myers CEO sagt, das Unternehmen sei im Umbruch

Am 09. Januar 2024 um 19:06 Uhr